Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Ensysce Biosciences, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 13 | 8 | −5 |
| Shares | 2.42M | 140.8K | −2.28M (−94.2%) |
| Value | $580.5K | $1.15M | +$565.4K (+97.4%) |
New holders (4)
Institutions that held Ensysce Biosciences, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Perceptive Advisors LLC | 86,666 | $705.5K | 0.02% |
| Adage Capital Partners GP, L.L.C. | 50,000 | $407.0K | 0.00% |
| FNY Investment Advisers, LLC | 3,000 | $24.0K | 0.01% |
| Morgan Stanley | 52 | $423 | 0.00% |
Sold out (9)
Institutions that held Ensysce Biosciences, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Sabby Management, LLC | 1,162,592 | $279.0K |
| Anson Funds Management LP | 983,518 | $236.0K |
| Geode Capital Management, LLC | 46,072 | $11.1K |
| Citadel Advisors LLC | 23,605 | $5.67K |
| Renaissance Technologies LLC | 22,400 | $5.38K |
| Cerity Partners LLC | 21,426 | $5.14K |
| HRT Financial LP | 23,558 | $5.00K |
| Vanguard Group Inc | 18,175 | $4.36K |
| FMR LLC | 1 | $0 |